Anavex/$AVXL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Anavex
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
Ticker
$AVXL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
42
ISIN
US0327973006
Website
Anavex Metrics
BasicAdvanced
$954M
-
-$0.56
0.82
-
Price and volume
Market cap
$954M
Beta
0.82
52-week high
$14.44
52-week low
$4.60
Average daily volume
952K
Financial strength
Current ratio
6.739
Quick ratio
6.699
Profitability
Management effectiveness
Return on assets (TTM)
-25.44%
Return on equity (TTM)
-40.17%
Valuation
Price to book
9.56
Price to tangible book (TTM)
9.56
Price to free cash flow (TTM)
-31.8
Free cash flow yield (TTM)
-3.14%
Free cash flow per share (TTM)
-35.16%
Growth
Earnings per share change (TTM)
12.67%
3-year earnings per share growth (CAGR)
-1.34%
10-year earnings per share growth (CAGR)
-5.64%
What the Analysts think about Anavex
Analyst ratings (Buy, Hold, Sell) for Anavex stock.
Bulls say / Bears say
Anavex Life Sciences reported a quarterly loss of $0.14 per share, surpassing analysts' expectations of a $0.17 loss, indicating better-than-anticipated financial performance. (etfdailynews.com)
Analysts have set optimistic price targets for Anavex, with HC Wainwright maintaining a 'buy' rating and a $40.00 target price, and D. Boral Capital issuing a $46.00 price objective, reflecting strong confidence in the company's growth potential. (defenseworld.net)
Anavex's stock reached a new 52-week high of $11.50 following its earnings report, demonstrating positive market reception and investor confidence. (etfdailynews.com)
Despite recent gains, Anavex's stock price experienced a 7.6% decline on December 30, 2024, indicating potential volatility and investor uncertainty. (americanbankingnews.com)
The company's net income for December 2024 was reported at a loss of $12.11 million, reflecting ongoing financial challenges. (google.com)
Anavex's cash and short-term investments decreased by 15.99% year-over-year to $120.78 million as of December 2024, potentially impacting its ability to fund future operations. (google.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Anavex Financial Performance
Revenues and expenses
Anavex Earnings Performance
Company profitability
Anavex News
AllArticlesVideos
ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Long-Term Investors to Contact the Firm
GlobeNewsWire·4 weeks ago
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
GlobeNewsWire·2 months ago
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Anavex stock?
Anavex (AVXL) has a market cap of $954M as of July 11, 2025.
What is the P/E ratio for Anavex stock?
The price to earnings (P/E) ratio for Anavex (AVXL) stock is 0 as of July 11, 2025.
Does Anavex stock pay dividends?
No, Anavex (AVXL) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Anavex dividend payment date?
Anavex (AVXL) stock does not pay dividends to its shareholders.
What is the beta indicator for Anavex?
Anavex (AVXL) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.